Nucleic acid products, kits and applications for detecting cervical cancer or precancerous lesions

By detecting the methylation level of specific gene regions, using nucleic acid combinations and kits, the problems of low sensitivity and poor specificity of existing cervical cancer screening methods are solved, and high sensitivity and high specificity of cervical cancer and precancerous lesions are achieved. Testing improves the accuracy of early diagnosis.

CN116024342BActive Publication Date: 2024-11-05WUHAN AIMISEN LIFE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211535966.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-02
Publication Date
2024-11-05
Estimated Expiration
2042-12-02

AI Technical Summary

Technical Problem

Existing cervical cancer screening methods such as liquid-based cytology detection and HPV detection have low sensitivity and poor specificity, resulting in missed diagnosis and past diagnosis problems, making it difficult to accurately identify high-level cervical precancerous lesions, and new detection methods are urgently needed.

Method used

By detecting the methylation levels of Chr6:27558279-27558522bp and Chr6:104953064-104953268bp regions, the diagnosis of cervical cancer or precancerous lesions was performed using nucleic acid combinations and kits, and combining methylation fluorescence quantitative PCR to improve the sensitivity of detection and Specificity.

Benefits of technology

It significantly improves the detection rate of cervical cancer and cervical intraepithelial neoplasia, has high detection sensitivity and high specificity, and can effectively distinguish healthy people from patients with lesions, especially in early diagnosis, showing high sensitivity and specificity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present application relates to nucleic acid products, kits and applications for detecting cervical cancer or precancerous lesions. The present application provides a nucleic acid combination for detecting cervical cancer or precancerous lesions, the nucleic acid combination comprising a nucleic acid combination for detecting the methylation level of the Chr6:27558279-27558522 region, and / or a nucleic acid combination for detecting the methylation level of the Chr6:104953064-104953268 region. The present application uses a partial region or full length of the target fragment Chr6:27558279-27558522bp and Chr6:104953064-104953268bp as a biomarker, and by detecting the methylation level of the region, cervical cancer or cervical intraepithelial neoplasia can be diagnosed or auxiliary diagnosed, with high sensitivity and specificity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of molecular biology, and in particular to nucleic acid products, kits and applications for detecting cervical cancer or precancerous lesions. Background Art

[0002] Cervical cancer is the most common malignant tumor in the female reproductive tract and ranks second among the causes of cancer deaths among women worldwide, which seriously endangers women's health. According to data from the World Health Organization, there will be approximately 604,000 new cases of cervical cancer in the world in 2020, and approximately 340,000 people will die from the disease throughout the year. Persistent infection with human papillomavirus (HPV) is a necessary factor for the occurrence of cervical cancer. Some HPV infections can be repaired by the immune system and automatically return to normal, while other persistent high-risk HPV infections can lead to high-grade cervical intraepithelial neoplasia (CIN), which then develops into cancer. However, it may take decades for normal cervical cells to develop into cervical cancer through precancerous lesions. This provides an excellent time window for early diagnosis and prevention of cervical cancer. The cure rate of early cervical precancerous lesions discovered through early diagnosis can reach 100%.

[0003] Currently, the main means of cervical cancer screening are liquid-based cytology testing (TCT) and HPV testing. However, the sensitivity of cytology testing is as low as only about 60%, and the specificity of HPV testing is poor. Among people who have cervical squamous cells tested by cytology, only 40-60% will test positive for HPV, and among them, less than 1% will be diagnosed with cancer. The problems of missed diagnosis and overdiagnosis caused by the shortcomings of the two methods have been plaguing clinical practice. There is an urgent need for new detection methods to accurately identify high-grade lesions for early diagnosis or auxiliary diagnosis of cervical cancer. Summary of the invention

[0004] Based on this, it is necessary to provide a nucleic acid combination, reagents and kit for detecting cervical cancer or precancerous lesions, which can effectively distinguish healthy people from patients with cervical cancer and cervical intraepithelial neoplasia.

[0005] The specific technical solutions are as follows:

[0006] A nucleic acid combination for detecting cervical cancer or precancerous lesions, the nucleic acid combination comprising a nucleic acid combination for detecting the methylation level of the full length and partial region of Chr6:27558279-27558522 region, and / or a nucleic acid combination for detecting the methylation level of the full length and partial region of Chr6:104953064-104953268 region.

[0007] In one embodiment, the nucleic acid combination for detecting the methylation level of the full-length and partial regions of the Chr6:27558279-27558522 region includes at least one of a first nucleic acid combination and a second nucleic acid combination.

[0008] In one embodiment, the nucleic acid combination for detecting the methylation level of the full-length and partial regions of the Chr6:104953064-104953268 region includes at least one of the third nucleic acid combination and the fourth nucleic acid combination.

[0009] In one embodiment, the first nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.1-2. The second nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.4-5. The third nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.7-8. The fourth nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.10-11.

[0010] In one embodiment, the first nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.3; the second nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.6; the third nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.9; and the fourth nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.12.

[0011] A reagent or kit comprising any of the above-mentioned nucleic acid combinations for detecting cervical cancer or precancerous lesions.

[0012] In one embodiment, the kit further includes at least one of a sampling device for tissue samples or cervical exfoliated cell samples, a nucleic acid extraction reagent, and a nucleic acid purification reagent.

[0013] The use of a nucleic acid combination in the preparation of a product for diagnosing cervical cancer or precancerous lesions, the nucleic acid combination comprising a nucleic acid combination for detecting the methylation level of a target region, the target region comprising the full length or partial region of at least one of the following regions: Chr6:27558279-27558522 region and Chr6:104953064-104953268 region.

[0014] In one embodiment, the partial region of the Chr6:27558279-27558522 region includes one or more of region 1 and region 2.

[0015] In one embodiment, the portion of the Chr6:104953064-104953268 region includes one or more of region 3 and region 4.

[0016] In one embodiment, the region 1 is the positive chain of Chr6:27558279-27558453; the region 2 is the negative chain of Chr6:27558390-27558522; the region 3 is the positive chain of Chr6:104953064-104953255; and the region 4 is the negative chain of Chr6:104953101-104953268.

[0017] In one embodiment, the target area includes at least one of area 1 to area 4.

[0018] Optionally, the target area includes at least one of area 1 to area 2, and contains at least one of area 3 to area 4.

[0019] In one embodiment, the nucleic acid combination includes at least one of a first nucleic acid combination, a second nucleic acid combination, a third nucleic acid combination, and a fourth nucleic acid combination.

[0020] The first nucleic acid combination includes a primer pair with a nucleotide sequence as shown in SEQ ID NOs.1 to 2; the second nucleic acid combination includes a primer pair with a nucleotide sequence as shown in SEQ ID NOs.4 to 5; the third nucleic acid combination includes a primer pair with a nucleotide sequence as shown in SEQ ID NOs.7 to 8; and the fourth nucleic acid combination includes a primer pair with a nucleotide sequence as shown in SEQ ID NOs.10 to 11.

[0021] Optionally, the first nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.3; the second nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.6; the third nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.9; and the fourth nucleic acid combination also includes a probe whose nucleotide sequence is shown in SEQ ID NO.12.

[0022] In one embodiment, the precancerous lesion includes cervical intraepithelial neoplasia.

[0023] Compared with the prior art, this application has the following beneficial effects:

[0024] The present application discovered that by using a partial region or the full length of the target fragment Chr6: 27558279-27558522bp and / or Chr6: 104953064-104953268bp as a biomarker, the methylation level of the region can be detected to diagnose or assist in the diagnosis of cervical cancer or cervical intraepithelial neoplasia, with high sensitivity and specificity, which can effectively improve the detection rate of cervical cancer or cervical intraepithelial neoplasia and contribute to the early diagnosis of cervical cancer.

[0025] The nucleic acid combination, reagent or kit provided in the present application can quickly and easily detect cervical cancer or cervical intraepithelial neoplasia with high sensitivity, high specificity and stable detection. DETAILED DESCRIPTION

[0026] In order to facilitate understanding of the present application, the present application will be described more comprehensively below. However, the present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the present application disclosure more thorough and comprehensive.

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.

[0028] Explanation of terms

[0029] The term "and / or" is intended to include any and all combinations of one or more of the associated listed items.

[0030] The term "cancer" refers to epithelial malignant tumors that occur in the cervix. Cervical cancer is divided into squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma is further divided into exophytic, endophytic, ulcerative and endocervical types. Adenocarcinoma is divided into common type and mucinous type.

[0031] The term "diagnosis" includes auxiliary diagnosis, recurrence risk assessment, assessment of cancer risk and degree, and prognosis.

[0032] The term "oligonucleotide" or "polynucleotide" or "nucleotide" or "nucleic acid" refers to a molecule having two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and usually more than ten. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be produced in any manner, including chemical synthesis, DNA replication, reverse transcription, or a combination thereof. The typical deoxyribonucleotides of DNA are thymine, adenine, cytosine, and guanine. The typical ribonucleotides of RNA are uracil, adenine, cytosine, and guanine.

[0033] The term "methylation" is a form of chemical modification of DNA that can change genetic expression without changing the DNA sequence. DNA methylation refers to the covalent attachment of a methyl group to the 5th carbon position of cytosine in genomic CpG dinucleotides under the action of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby controlling gene expression.

[0034] The term "methylation level" refers to whether the cytosine in one or more CpG dinucleotides in a DNA sequence is methylated, or the frequency / proportion / percentage of methylation, which represents both qualitative and quantitative concepts. In practical applications, different detection indicators can be used to compare DNA methylation levels according to actual conditions. For example, in some cases, the comparison can be made based on the Ct value of the sample test; in some cases, the proportion of gene methylation in the sample can be calculated, that is, the number of methylated molecules / (the number of methylated molecules + the number of unmethylated molecules) × 100%, and then compared; in some cases, it is also necessary to statistically analyze and integrate the various indicators to obtain the final judgment indicator.

[0035] The term "primer" refers to an oligonucleotide that can be used in an amplification method (e.g., polymerase chain reaction, PCR) to amplify a target sequence based on a polynucleotide sequence corresponding to a target gene or a portion thereof. Typically, at least one of the PCR primers used to amplify a polynucleotide sequence is sequence-specific for the polynucleotide sequence. The exact length of the primer depends on many factors, including temperature, primer source, and the method used. For example, for diagnostic and prognostic applications, oligonucleotide primers typically contain at least 10, 15, 20, 25 or more nucleotides, but may also contain fewer nucleotides, depending on the complexity of the target sequence. In the disclosure of this application, the term "primer" refers to a pair of primers that can hybridize with the double-stranded DNA of a target DNA molecule or can hybridize with a region located on both sides of a nucleotide sequence to be amplified in a target DNA molecule.

[0036] The term "TaqMan probe" refers to an oligonucleotide sequence containing a 5' fluorescent group and a 3' quencher group. When the probe binds to the corresponding site on the DNA, the probe will not emit fluorescence because of the presence of a quencher group near the fluorescent group. During the amplification process, if the probe binds to the amplified chain, the 5'-3' exonuclease activity of the DNA polymerase (such as Taq enzyme) will digest the probe, and the fluorescent group will be away from the quencher group, and its energy will not be absorbed, thus generating a fluorescent signal. After each PCR cycle, the fluorescent signal also has a synchronous exponential growth process like the target fragment.

[0037] One embodiment of the present application provides a nucleic acid combination for detecting cervical cancer or precancerous lesions, wherein the nucleic acid combination includes a nucleic acid combination for detecting the methylation level of the full length or partial region of Chr6:27558279-27558522 region, and / or a nucleic acid combination for detecting the methylation level of the full length or partial region of Chr6:104953064-104953268 region.

[0038] It should be noted that the regional positions mentioned in this application are based on GRCh38.p14 as the reference genome. The Chr6:27558279-27558522 region or the Chr6:104953064-104953268 region can refer to the positive strand of the DNA in the region or the negative strand of the DNA in the region.

[0039] In a specific example, the nucleic acid combination for detecting the methylation level of the whole length or part of the region of Chr6:27558279-27558522 includes at least one of the first nucleic acid combination and the second nucleic acid combination. The nucleic acid combination for detecting the methylation level of the whole length or part of the region of Chr6:104953064-104953268 includes at least one of the third nucleic acid combination and the fourth nucleic acid combination.

[0040] In a specific example, the first nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.1 to 2. The second nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.4 to 5. The third nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.7 to 8. The fourth nucleic acid combination includes a primer pair whose nucleotide sequence is shown as SEQ ID NO.10 to 11.

[0041] In a specific example, the first nucleic acid combination further includes a probe having a nucleotide sequence as shown in SEQ ID NO. 3. The second nucleic acid combination further includes a probe having a nucleotide sequence as shown in SEQ ID NO. 6. The third nucleic acid combination further includes a probe having a nucleotide sequence as shown in SEQ ID NO. 9. The fourth nucleic acid combination further includes a probe having a nucleotide sequence as shown in SEQ ID NO. 12.

[0042] In a specific example, the probe of the present application may be a TaqMan probe, a fluorescent group is connected to the 5' end thereof, and a fluorescent quenching group is connected to the 3' end thereof.

[0043] One embodiment of the present application provides a reagent or a kit, comprising any of the above-mentioned nucleic acid combinations for detecting cervical cancer or precancerous lesions.

[0044] In a specific example, the test sample of the reagent or kit includes a tissue sample or a cervical exfoliated cell sample. In other examples, the test sample may also include a blood sample, a urine sample, etc.

[0045] One embodiment of the present application also provides the use of a reagent for detecting methylation of a target region in the preparation of a diagnostic product for cervical cancer or precancerous lesions, wherein the target region includes the full length or partial region of at least one of the following regions: Chr6:27558279-27558522 region and Chr6:104953064-104953268 region.

[0046] In a specific example, cervical cancer includes cervical cancer stages I to IV. Precancerous lesions include cervical intraepithelial neoplasia, and optionally cervical intraepithelial neoplasia includes CIN stages II to III.

[0047] In one specific example, diagnosis includes auxiliary diagnosis or early diagnosis.

[0048] In a specific example, a diagnostic product may include a diagnostic system, a diagnostic kit or reagent, a diagnostic device, and the like.

[0049] In a specific example, a partial region of the Chr6:27558279-27558522 region includes one or more of region 1 and region 2. A partial region of the Chr6:104953064-104953268 region includes one or more of region 3 and region 4. Among them, region 1 is the positive strand of Chr6:27558279-27558453; region 2 is the negative strand of Chr6:27558390-27558522; region 3 is the positive strand of Chr6:104953064-104953255; and region 4 is the negative strand of Chr6:104953101-104953268.

[0050] In a specific example, the target area includes at least one of areas 1 to 4. Optionally, the target area includes at least one of areas 1 to 2, and includes at least one of areas 3 to 4. When the target area is a combination of two or more areas, the effect of diagnosing cervical cancer or precancerous lesions is better.

[0051] Optionally, the target area is selected from a combination of area 1 and area 3.

[0052] For cervical exfoliated cell samples, the sensitivity of this regional combination in diagnosing early and late cervical cancer patients has been significantly improved, reaching up to 94.12% and 97.14% respectively, and its detection specificity in healthy people has reached 95%. Its detection sensitivity for CIN III stage can reach up to 90%, and its detection sensitivity for CIN II stage can reach 64.29%.

[0053] For tissue samples, the regional combination has a detection sensitivity of 100% for late-stage cervical cancer and 97.73% for early-stage cancer. The detection sensitivity for CIN III is 91.94%, and the detection rate for CIN II is 70.59%. Its detection specificity for adjacent tissues is 86.90%.

[0054] In a specific example, the reagent includes any of the above-mentioned nucleic acid combinations. Optionally, the reagent also includes other reagents for determining the methylation level of the target region, such as DNA bisulfite conversion reagents, PCR reagents, etc.

[0055] In a specific example, the reagent detects methylation of the target region by one or more of the following methods:

[0056] Methylation-specific PCR, quantitative methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole-genome bisulfite sequencing, pyrosequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method.

[0057] One embodiment of the present application also provides a method for diagnosing cervical cancer or precancerous lesions using the methylation level of the above target region, comprising the following steps:

[0058] Detecting the methylation level of the above target region; and

[0059] Whether the sample to be tested is a positive sample is determined based on the methylation level of the target region.

[0060] Optionally, when the target area is a combination of multiple areas, the determination method is that when the Ct value of at least one area is less than or equal to the threshold, the sample to be tested is considered to be a positive sample, that is, cervical cancer or precancerous lesions are positive. The threshold is a cutoff value when the Youden index is the maximum selected as the threshold by a technician in this field through ROC curve analysis of a sample set of cervical cancer or precancerous lesions patients and healthy people. Different thresholds may be selected for different types of samples. Specific embodiments

[0062] The embodiments of the present application will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0063] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0064] Example 1

[0065] The performance of methylation fluorescence quantitative PCR in analyzing target regions in diagnosing tissue samples from patients with cervical cancer or CIN.

[0066] The inventors have discovered that by detecting the methylation level of a combination of any region selected from Chr6: 27558279-27558522bp and any region selected from Chr6: 104953064-104953268bp in tissue samples from cervical cancer patients or CIN patients, cervical cancer and precancerous lesion tissue samples and adjacent normal tissue samples can be effectively distinguished. The specific detection process is shown below.

[0067] 1. Collection of Tissue Samples

[0068] A total of 40 cancer tissue samples from patients with advanced cervical cancer (stage III or IV) confirmed by pathological examination, 44 cancer tissue samples from patients with early cervical cancer (stage I or II), and 84 corresponding adjacent normal tissue samples were collected; 62 pathological tissue samples from patients with CIN stage III were collected; and 34 pathological tissue samples from patients with CIN stage II were collected. All samples were formalin-soaked and paraffin-embedded tissue samples. The collection process of all samples was approved by the Ethics Committee, all volunteers signed informed consent forms, and all samples were anonymized.

[0069] 2. Extraction of Sample DNA

[0070] QIAamp DNA FFPE Tissue Kit (Cat: 56404) was used to extract DNA from tissue samples, and the specific operations were carried out according to the instructions of the kit.

[0071] 3. Transformation of sample DNA

[0072] The kits used for conversion and purification of sample DNA are all nucleic acid conversion reagents of Wuhan Aimisen Life Science Technology Co., Ltd. (Ehan Equipment No. 20200843). The specific operation steps are as follows: add 40 μL of extracted DNA solution to a 200 μL PCR tube, add 110 μL of conversion mixture, mix well and place in a PCR instrument, and set the program as follows: 95°C for 10 min, 64°C for 90 min, and 4°C for 1 h.

[0073] 4. Purification of sample DNA

[0074] 1) Transfer the transformation product to a 2mL centrifuge tube, add 600μL binding solution and 10μL magnetic beads, mix well and let stand for 15min, shake and mix for 5s every 3min to keep the magnetic beads in suspension; centrifuge briefly, place the centrifuge tube on the magnetic rack, and carefully remove the supernatant after the magnetic beads are completely adsorbed (about 1min). 2) Add 600μL rinsing solution, vortex mix for 20s to disperse the magnetic beads; centrifuge briefly, place the centrifuge tube on the magnetic rack, and carefully remove the supernatant after the magnetic beads are completely adsorbed (about 1min). 3) Add 800μL desulfurizer, vortex mix for 20s to disperse the magnetic beads, let stand for 15min desulfurization at room temperature, shake and mix for 5s every 5min to keep the magnetic beads in suspension. 4) Add 800μL rinsing solution, vortex mix for 20s to disperse the magnetic beads; centrifuge briefly, place the centrifuge tube on the magnetic rack, and carefully remove the supernatant after the magnetic beads are completely adsorbed (about 1min). 5) Repeat step 4) once. 6) Centrifuge briefly to collect the liquid to the bottom of the tube, place the centrifuge tube on a magnetic rack, and carefully aspirate the supernatant; open the lid and place at 25°C for about 5 minutes until the surface of the magnetic beads is dull. 7) Add 30μL of elution buffer TE, vortex to fully suspend the magnetic beads in the elution buffer, incubate at 56°C for 10 minutes, and vortex every 3 minutes to promote full elution of nucleic acids. 8) Centrifuge briefly, place the centrifuge tube on a magnetic rack and let it stand for 2 minutes, and transfer the DNA solution to a new centrifuge tube.

[0075] 5. Methylation Fluorescence Quantitative PCR Reaction

[0076] In order to ensure that the amplification efficiency of the fluorescence quantitative PCR reaction is between 95% and 105%, and there is no non-specific amplification and primer dimer, the sequences of Chr6: 27558279-27558522bp and Chr6: 104953064-104953268bp after bisulfite conversion are used as templates to design multiple pairs of primers for methylation fluorescence quantitative PCR reaction. Then the primer pairs are verified, the target fragment is amplified using the SYBR Green PCR system, and two pairs of primers for amplifying the partial region of Chr6: 27558279-27558522bp and two pairs of primers for amplifying the partial region of Chr6: 104953064-104953268bp that meet the above requirements are screened through melting curve and standard curve analysis, and corresponding TaqMan detection probes are designed for each pair of primers for use in the TaqMan PCR reaction system. The target regions detected by each primer pair and probe and the primer pairs and detection probes for detecting each target region are shown in Table 1. The primer pair and detection probe of the internal reference gene ACTB also need to be added to the reaction system. The upstream amplification primer of the internal reference gene ACTB is: AAGGTGGTTGGGTGGTTGTTTTG (SEQ ID NO: 13), the downstream amplification primer is: AATAACACCCCACCCTGC (SEQ ID NO: 14), and the detection probe is: GGAGTGGTTTTTGGGTTTG (SEQ ID NO: 15).

[0077] Table 1 Primer and probe sequences for each target region

[0078]

[0079] The amplification reaction system is: 5 μL of 5× Platinum II PCR buffer, 0.5 μL of 10 μM target region upstream primer, 0.5 μL of 10 μM target region downstream primer, 0.5 μL of 10 μM target region probe, 0.5 μL of 10 μM ACTB upstream primer, 0.5 μL of 10 μM ACTB downstream primer, 0.5 μL of 10 μM ACTB detection probe, Platinum II TM II Taq Hot-Start DNA Polymerase 0.5μL, 10mM dNTPs 1μL, 5μL of the sample DNA to be tested, and make up to 25μL with purified water.

[0080] The reaction conditions were as follows: pre-denaturation at 98°C for 10 min; denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and supplementary extension at 72°C for 5 min (fluorescence was collected during annealing and supplementary extension), for a total of 47 cycles; and storage at 4°C.

[0081] Negative control and positive control: When performing PCR reaction to detect samples, negative control and positive control should also be tested at the same time. The DNA template of the negative control tube is TE buffer. The preparation method of the DNA template of the positive control tube is: artificially synthesize the sequence corresponding to the ACTB gene amplification region that has been completely converted by bisulfite, and clone it into the vector to form an artificial synthetic plasmid; artificially synthesize the target region and clone it into the vector separately to form an artificial synthetic plasmid. If only the methylation level of a single region is detected, the positive control DNA template is 10 3 Copies / μl of artificial synthetic plasmid containing transformed ACTB, 10 3 The synthetic plasmid containing the detection region is mixed in a ratio of 1:1; if the methylation level of the detection region composition is determined according to Table 3, the positive control DNA template is 10 3 Copies / μl of artificial synthetic plasmid containing transformed ACTB, 10 3 Copies / μl of a synthetic plasmid containing a target region and 10 3 Copies / μl of an artificially synthesized plasmid containing another target region, and the three were mixed in a 1:1:1 ratio.

[0082] Ct value reading: After PCR is completed, adjust the baseline, set the fluorescence value 1-2 cycles before the minimum Ct value of the sample in a PCR as the baseline value, set the threshold at the inflection point of the S-shaped amplification curve, and obtain the Ct value of each gene in the sample.

[0083] Quality control: The negative control should have no amplification, the positive control should have an obvious exponential growth period, and the Ct value of each gene in the positive control should be between 26-30. The Ct value of the internal reference gene of the sample to be tested should be ≤35. If the negative control, positive control and internal reference gene meet the above requirements, it indicates that this experiment is valid and the next step of sample result determination can be carried out. Otherwise, the experiment is invalid and must be retested.

[0084] 6. PCR Results Analysis

[0085] The methylation level of the sample to be tested is determined based on the Ct value detected in each target region. For tissue samples, if the Ct value of amplifying a certain region is ≤38, this region in the sample is considered to be methylation-positive, and if the Ct value of amplifying a certain region is >38, this region in the sample is considered to be methylation-negative. When a single region is used as a detection marker, if the sample to be tested is methylation-positive in this region, then the sample is a cancer-positive sample, and if the sample to be tested is methylation-negative in this region, then the sample is a cancer-negative sample. When two regions are combined as detection markers, if at least one region in the region combination of the sample to be tested is methylation-positive, then the sample is a cancer-positive sample, and only when both regions in the two region combinations of the sample to be tested are methylation-negative, then the sample is a cancer-negative sample.

[0086] The sensitivity and specificity of diagnosing cervical cancer tissue samples, precancerous lesion tissue samples, and adjacent normal tissue samples by detecting the methylation levels of regions 1 to 4 using the methylation fluorescence quantitative PCR detection method are shown in Table 2. The sensitivity and specificity of diagnosing cervical cancer tissue samples and adjacent normal tissue samples by detecting the methylation levels of a combination of region 1 or region 2 and any of regions 3 and 4 are shown in Table 3.

[0087] Table 2. Methylation status of regions 1 to 4 in tissue samples and their diagnostic sensitivity and specificity

[0088]

[0089] Table 3. Methylation status of regional combinations in tissue samples and diagnostic sensitivity and specificity

[0090]

[0091] As can be seen from Tables 2 and 3, compared with the methylation level of a single region in Regions 1 to 4, the detection sensitivity and specificity of the regional combination are significantly improved, especially when the combination of Region 1 + Region 3 is used for detection, the detection sensitivity for advanced cancer tissue samples can reach 100%, and the detection sensitivity for early cancer tissue samples is 97.73%. At the same time, it has a good detection effect on precancerous lesions, with a detection sensitivity of 91.94% for CIN III and a detection rate of 70.59% for CIN II. In addition, the detection specificity of the combination of Region 1 + Region 3 for adjacent cancer tissues is 86.90%.

[0092] Example 2

[0093] The performance of regional composition in diagnosing cervical exfoliated cell samples of patients with cervical cancer or CIN was analyzed by methylation fluorescence quantitative PCR.

[0094] By detecting the methylation level of a combination of any region selected from Chr6: 27558279-27558522bp and any region selected from Chr6: 104953064-104953268bp in cervical exfoliated cells extracted from cervical swabs of cervical cancer patients or CIN patients, patients with cervical cancer and precancerous lesions and healthy people can be effectively distinguished. The specific detection process is shown below.

[0095] 1. Collection of cervical exfoliated cell samples

[0096] A total of 35 cervical exfoliated cell samples from patients with advanced cervical cancer (stage III or IV) confirmed by pathological examination, 34 cervical exfoliated cell samples from patients with early cervical cancer (stage I or II) were collected; 30 cervical exfoliated cell samples from patients with CIN stage III; 28 cervical exfoliated cell samples from patients with CIN stage II, and 60 cervical exfoliated cell samples from healthy people undergoing routine physical examinations. The collection process of all samples was approved by the ethics committee, all volunteers signed informed consent, and all samples were anonymized.

[0097] 2. Sample DNA Extraction

[0098] The nucleic acid extraction kit (Ehan Medical No. 20210836) of Wuhan Aimisen Life Science Technology Co., Ltd. was used to extract DNA from exfoliated cell samples. The specific steps are as follows.

[0099] 1) Cleavage and binding

[0100] Prepare a clean 5 mL centrifuge tube and add 100 μL of proteinase K. Mix the exfoliated cell sample and take 2 mL into the centrifuge tube prepared with proteinase K, add 2 mL of lysis binding solution and 20 μL of magnetic beads in sequence, mix by inverting, and place on a mixer at 25°C for 30 min to lyse, keeping the magnetic beads in suspension.

[0101] 2) Washing

[0102] Place the centrifuge tube on the magnetic rack and magnetize for 2 minutes. After the solution is clear, invert it several times to rinse the remaining magnetic beads on the tube cap until all the magnetic beads are completely attracted. Carefully remove the waste liquid, add 2mL of washing solution, vortex mix more than 10 times to completely disperse the magnetic beads, magnetize again for 2 minutes. After the solution is clear, invert it several times to rinse the remaining magnetic beads on the tube cap until all the magnetic beads are completely attracted.

[0103] 3) Rinse

[0104] Carefully remove the waste liquid, first add 500μL of rinsing solution to wash the magnetic beads to the bottom, then transfer the magnetic bead suspension to a new 2mL centrifuge tube, then add 500μL of rinsing solution to completely wash the residual magnetic beads on the wall of the 5mL centrifuge tube to the bottom, transfer all the magnetic bead suspension to a 2mL centrifuge tube after instant centrifugation, vortex mix more than 10 times to completely disperse the magnetic beads, absorb the magnet for 2 minutes, and after the solution is clear, invert several times to rinse the residual magnetic beads on the tube cover until all the magnetic absorption is completed. Repeat the rinse once.

[0105] 4) Elution

[0106] Remove the centrifuge tube and centrifuge briefly to collect the remaining liquid. After the magnet is absorbed, use a small gun tip to remove the remaining liquid. Leave the centrifuge tube open for 5 minutes to make the surface of the magnetic beads dull. Add 50μL of elution solution TE (Tris-EDTA buffer solution, TE buffer), gently shake to disperse the magnetic beads, place at 56℃ for 10 minutes, and take out and shake gently every 3 minutes to keep the magnetic beads in suspension.

[0107] 5) Collect DNA solution

[0108] Take out the centrifuge tube, collect the liquid on the tube cap and the tube wall by centrifugation, place it on a magnetic rack to absorb the magnet for 1 minute, and carefully aspirate the supernatant to obtain the DNA solution.

[0109] 3. The sample DNA conversion and purification methods are the same as in Example 1.

[0110] 4. The detection method of methylation fluorescence quantitative PCR is the same as that in Example 1.

[0111] Since the effect of detecting the methylation level of a certain region in regions 1 to 4 alone to distinguish cancer tissue samples from normal tissue samples is not as significant as the effect of the region combination (see Table 3), in this embodiment, the methylation level of a certain region in the exfoliated cell sample is no longer detected alone, but the methylation level of the region combination in the sample is detected.

[0112] 5. Analysis of methylation fluorescence quantitative PCR results

[0113] The reading and quality control of Ct value are the same as those in Example 1.

[0114] PCR result analysis and interpretation method: For exfoliated cell samples, if the Ct value of the sample to be tested in a certain detection area is ≤38, the sample is considered to be methylation-positive in this area; if the Ct value of the sample to be tested in a certain detection area is >38, the sample is considered to be methylation-negative in this area. When a combination of two regions is used as a detection marker, if at least one region of the region combination of the sample to be tested is methylation-positive, the sample is a cancer-positive sample; only when both regions of the sample to be tested in the two region combinations are methylation-negative, the sample is a cancer-negative sample.

[0115] Table 4 shows the sensitivity and specificity of diagnosing cervical exfoliated cells by using the methylation fluorescence quantitative PCR detection method by detecting the methylation level of the combination of region 1 to region 2 and any region in region 3 to region 4.

[0116] Table 4. Methylation status of regional combinations in exfoliated cells and sensitivity and specificity of diagnosis

[0117]

[0118] As can be seen from Table 4, the methylation fluorescence quantitative PCR method has good effect in diagnosing cervical cancer patients and healthy people when the methylation levels of the combination of regions 1 to 2 and any of regions 3 to 4 are detected simultaneously. Among them, when region 1 is combined with region 3, the sensitivity of diagnosing cervical exfoliated cell samples of patients with early and late cervical cancer is significantly improved, reaching up to 94.12% and 97.14% respectively; its specificity in healthy people reaches 95%. At the same time, the combination of region 1 and region 3 has a good effect in detecting cervical precancerous lesions. As can be seen from Table 4, its detection sensitivity for cervical exfoliated cell samples of patients with stage III cervical epithelial tumor lesions can reach up to 90%; its detection sensitivity for cervical exfoliated cell samples of patients with stage II cervical epithelial tumor lesions can also reach 64.29%. In general, the performance of diagnosing cervical cancer and precancerous lesions by detecting the methylation level of the regional combination of combination A is the best.

[0119] Example 3

[0120] This embodiment provides a kit for diagnosing or assisting diagnosis of cervical cancer, which includes a nucleotide combination 1, which includes a nucleotide sequence as shown in SEQ ID NO. 1-3, and the specific sequence is shown in Table 1. The nucleotide combination 1 can detect methylation of the positive strand (region 1) of the Chr6: 27558279-27558453bp region.

[0121] The positive strand base sequence of region 1 is shown in SEQ ID NO.16 (5'-3'):

[0122] AGTGACGGTCGTATTTGTTTCTGTCACATTGCACCAAGCCATCTTTGGGTCGCAGATCACCTGAGATTTCTTCTCTTCCCTCCACAATTCTCCTCCCGTTTCTCAGACCACAAATGGTCGCCAGTTTCACTTCGCCAAACTTGGATTCTCCCGCGCTTGAGCGTCACTTTCAACG.

[0123] The nucleotides shown in SEQ ID NO.1-3 can detect the methylation of cytosine at positions Chr6:27558284, Chr6:27558288, Chr6:27558375, Chr6:27558397, Chr6:27558430, Chr6:27558432, Chr6:27558440, and Chr6:27558452 on the positive strand of the region.

[0124] Example 4

[0125] This embodiment provides a kit for diagnosis or auxiliary diagnosis of cervical cancer or precancerous lesions, which includes a nucleotide combination 2, which includes a nucleotide sequence as shown in SEQ ID NO. 4-6, and the specific sequence is shown in Table 1. The nucleotide combination 2 can detect the methylation of the negative strand (region 2) of the Chr6: 27558390-27558522bp region.

[0126] The base sequence of the negative strand of region 2 is shown in SEQ ID NO.17 (5'-3'):

[0127] CGGTACTTGCTCCGTTAGGGGCGGTCAATTAAGTGGCTTCTTGTCGTCCTGGACAGAAAGGAATGAAGTCGTTGAAAGTGACGCTCAAGCGCGGGAGAATCCAAGTTTGGCGAAGTGAAACTGGCGACCATTT.

[0128] The nucleotides shown in SEQ ID NO.4-6 can detect the methylation of cytosine at positions Chr6:27558398, Chr6:27558412, Chr6:27558431, Chr6:27558433, Chr6:27558441, Chr6:27558453, Chr6:27558501, Chr6:27558510, and Chr6:27558522 on the negative strand of the region.

[0129] Example 5

[0130] This embodiment provides a kit for diagnosing cervical cancer or assisting in the diagnosis of precancerous lesions, which includes nucleotide combination 3, which includes nucleotide sequences as shown in SEQ ID NO.7-9, and the specific sequences are shown in Table 1. The nucleotide combination 3 can detect the methylation of the positive strand (region 3) of the Chr6: 104953064-104953255bp region.

[0131] The positive strand base sequence of region 3 is shown in SEQ ID NO.18 (5'-3'):

[0132] TTTACCAAAACGCGGCGGAAGGAATCAGGACAGTTTGCCCGACGGGCGGGTCGGCGGCTTTCAGGCGGGAGATCCAGGGGCAGAGAGATCCCGAAAATCGCCCCCAGCCTTGCGTCCAGCCCTTTCTCGCCGACGTTTTTTCTTGATCCTCCGAAGGCCCAGGGCGACGTTTGCCATCGCGGCT.

[0133] The nucleotides shown in SEQ ID NO.7-9 can detect the methylation of cytosine at positions Chr6:104953074, Chr6:104953076, Chr6:104953079, Chr6:104953103, Chr6:104953106, Chr6:104953110, Chr6:104953115, Chr6:104953118, Chr6:104953236, Chr6:104953239, Chr6:104953249, and Chr6:104953251 on the positive strand of the region.

[0134] Example 6

[0135] This embodiment provides a kit for diagnosis or auxiliary diagnosis of cervical cancer or precancerous lesions, which includes a nucleotide combination 4, which includes a nucleotide sequence as shown in SEQ ID NO. 10-12, and the specific sequence is shown in Table 1. The nucleotide combination 4 can detect the methylation of the negative strand (region 4) of the Chr6: 104953101-104953268bp region.

[0136] The base sequence of the negative strand of region 4 is shown in SEQ ID NO.19 (5'-3'):

[0137] CGTCCTTTCGGGAAGCCGCGATGGCAAACGTCGCCCTGGGCCTTCGGAGGATCAAGAAAAAACGTCGGCGAGAAAGGGCTGGACGCAAGGCTGGGGGCGATTTCGGGATCTCTCTGCCCCTGGCAAGATCTCTCCCGCCTGAAAGCCGCCGACCCGCCCGTCGGG.

[0138] The nucleotides shown in SEQ ID NO.10-12 can detect the methylation of cytosine at positions Chr6:104953104, Chr6:104953107, Chr6:104953111, Chr6:104953116, Chr6:104953119, Chr6:104953185, Chr6:104953200, Chr6:104953203, Chr6:104953206, Chr6:104953250, Chr6:104953252, Chr6:104953260, and Chr6:104953268 on the negative strand of the region.

[0139] Example 7

[0140] This embodiment provides a kit for diagnosis or auxiliary diagnosis of cervical cancer or precancerous lesions, which includes at least one of the following combinations: a combination of nucleotide combination 1 and nucleotide combination 3, a combination of nucleotide combination 1 and nucleotide combination 4, a combination of nucleotide combination 2 and nucleotide combination 3, and a combination of nucleotide combination 2 and nucleotide combination 4. Wherein, nucleotide combination 1 includes the nucleotide sequence shown in SEQ ID NO.1-3, nucleotide combination 2 includes the nucleotide sequence shown in SEQ ID NO.4-6, nucleotide combination 3 includes the nucleotide sequence shown in SEQ ID NO.7-9, and nucleotide combination 4 includes the nucleotide sequence shown in SEQ ID NO.10-12.

[0141] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0142] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims, and the description may be used to interpret the content of the claims.

Claims

1. A nucleic acid combination for detecting cervical cancer or cervical intraepithelial neoplasia CIN III, characterized in that: The nucleic acid combination includes a primer pair with a nucleic acid sequence as shown in SEQ ID NO: 1-2 and a probe with a nucleotide sequence as shown in SEQ ID NO: 3, and a primer pair with a nucleotide sequence as shown in SEQ ID NO: 7-8 and a probe with a nucleotide sequence as shown in SEQ ID NO:

9.

2. A kit for detecting cervical cancer or cervical intraepithelial neoplasia CIN III, characterized in that: Comprising the nucleic acid combination of claim 1.

3. The kit according to claim 2, characterized in that The kit also includes at least one of a sampling device for tissue samples or cervical exfoliated cell samples, a nucleic acid extraction reagent or a nucleic acid purification reagent.

4. Use of the nucleic acid combination according to claim 1 in the preparation of a diagnostic product for cervical cancer or cervical intraepithelial neoplasia CIN III stage.